Literature DB >> 16887987

Dendritic cell-lysosomal-associated membrane protein (LAMP) and LAMP-1-HIV-1 gag chimeras have distinct cellular trafficking pathways and prime T and B cell responses to a diverse repertoire of epitopes.

Luciana B Arruda1, Del Sim, Priya R Chikhlikar, Milton Maciel, Kenji Akasaki, J Thomas August, Ernesto T A Marques.   

Abstract

Ag processing is a critical step in defining the repertoire of epitope-specific immune responses. In the present study, HIV-1 p55Gag Ag was synthesized as a DNA plasmid with either lysosomal-associated membrane protein-1 (LAMP/gag) or human dendritic cell-LAMP (DC-LAMP/gag) and used to immunize mice. Analysis of the cellular trafficking of these two chimeras demonstrated that both molecules colocalized with MHC class II molecules but differed in their overall trafficking to endosomal/lysosomal compartments. Following DNA immunization, both chimeras elicited potent Gag-specific T and B cell immune responses in mice but differ markedly in their IL-4 and IgG1/IgG2a responses. The DC-LAMP chimera induced a stronger Th type 1 response. ELISPOT analysis of T cell responses to 122 individual peptides encompassing the entire p55gag sequence (15-aa peptides overlapping by 11 residues) showed that DNA immunization with native gag, LAMP/gag, or DC-LAMP/gag induced responses to identical immunodominant CD4+ and CD8+ peptides. However, LAMP/gag and DC-LAMP/gag plasmids also elicited significant responses to 23 additional cryptic epitopes that were not recognized after immunization with native gag DNA. The three plasmids induced T cell responses to a total of 39 distinct peptide sequences, 13 of which were induced by all three DNA constructs. Individually, DC-LAMP/gag elicited the most diverse response, with a specific T cell response against 35 peptides. In addition, immunization with LAMP/gag and DC-LAMP/gag chimeras also promoted Ab secretion to an increased number of epitopes. These data indicate that LAMP-1 and DC-LAMP Ag chimeras follow different trafficking pathways, induce distinct modulatory immune responses, and are able to present cryptic epitopes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16887987     DOI: 10.4049/jimmunol.177.4.2265

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.

Authors:  Jeremy M Luke; Gregory G Simon; Jonas Söderholm; John S Errett; J Thomas August; Michael Gale; Clague P Hodgson; James A Williams
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

2.  Comparative analysis of antigen-targeting sequences used in DNA vaccines.

Authors:  Joana A Carvalho; Adriano R Azzoni; Duarte M F Prazeres; Gabriel A Monteiro
Journal:  Mol Biotechnol       Date:  2010-03       Impact factor: 2.695

3.  A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease.

Authors:  Carylinda Serna; Joshua A Lara; Silas P Rodrigues; Alexandre F Marques; Igor C Almeida; Rosa A Maldonado
Journal:  Vaccine       Date:  2014-04-30       Impact factor: 3.641

4.  Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia Virus.

Authors:  Maria Luiza G Medaglia; Nissin Moussatché; Andreas Nitsche; Pjotr Wojtek Dabrowski; Yu Li; Inger K Damon; Carolina G O Lucas; Luciana B Arruda; Clarissa R Damaso
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

Review 5.  Novel vaccines: Technology and development.

Authors:  Sarita U Patil; Wayne G Shreffler
Journal:  J Allergy Clin Immunol       Date:  2018-06-30       Impact factor: 10.793

6.  Cyclophilin A as a potential genetic adjuvant to improve HIV-1 Gag DNA vaccine immunogenicity by eliciting broad and long-term Gag-specific cellular immunity in mice.

Authors:  Jue Hou; Qicheng Zhang; Zheng Liu; Shuhui Wang; Dan Li; Chang Liu; Ying Liu; Yiming Shao
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

7.  PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines.

Authors:  Bingbing Dai; Liang Xiao; Paul D Bryson; Jinxu Fang; Pin Wang
Journal:  Mol Ther       Date:  2012-05-15       Impact factor: 11.454

8.  Activation of human CD4+ T cells by targeting MHC class II epitopes to endosomal compartments using human CD1 tail sequences.

Authors:  Kayvan R Niazi; Maria-Teresa Ochoa; Peter A Sieling; Nanette E Rooke; Anna K Peter; Pamela Mollahan; Micah Dickey; Shahrooz Rabizadeh; Thomas H Rea; Robert L Modlin
Journal:  Immunology       Date:  2007-07-16       Impact factor: 7.397

9.  Comparison of DNA vaccines producing HIV-1 Gag and LAMP/Gag chimera in rhesus macaques reveals antigen-specific T-cell responses with distinct phenotypes.

Authors:  Antonio Valentin; Priya Chikhlikar; Vainav Patel; Margherita Rosati; Milton Maciel; Kern-Hee Chang; Peter Silvera; Barbara K Felber; George N Pavlakis; J Thomas August; Ernesto T A Marques
Journal:  Vaccine       Date:  2009-06-17       Impact factor: 3.641

10.  Dendritic cell mediated delivery of plasmid DNA encoding LAMP/HIV-1 Gag fusion immunogen enhances T cell epitope responses in HLA DR4 transgenic mice.

Authors:  Gregory G Simon; Yongli Hu; Asif M Khan; Jingshi Zhou; Jerome Salmon; Priya R Chikhlikar; Keun-Ok Jung; Ernesto T A Marques; J Thomas August
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.